ABSTRACT
PURPOSE: whilst renal scintigraphy (RS) can be associated with interobserver variability, it remains the standard method of evaluating split renal function. AIM: to compare the efficacy of the novel technique of kidney function assessment and renal scintigraphy. METHOD: for this prospective single-arm study we recruited patients who were recommended dynamic renal scintigraphy with 99mTc-DTPA (diethylenetriaminepentacetate). After scintigraphy, mathematical analysis of computed tomography (MACT) was done in all patients, by a single person (SK) blinded to RS results. RESULTS: the study included a total of 97 patients with mean age of 50.9 (range, 23-78) years. From this sample, 65 were females and 32 males. All patients underwent both RS and contrast-enhanced computed tomography for further MACT in 2016-2018. CT results were found to be similar to renal scintigraphy results with Pearson correlation coefficient of 0.945 (Ñ < 0.001). Substantial similarities in renal plasma flow for both kidneys were also observed (0.815, Ñ < 0.001). CONCLUSION: MACT proved feasible, effective and safe in estimating renal function. Its results are closely correlated with RS findings and could be easily integrated into surgical practice.
Subject(s)
Contrast Media , Kidney/diagnostic imaging , Kidney/physiopathology , Radiographic Image Enhancement/methods , Tomography, X-Ray Computed/methods , Tomography, X-Ray Computed/statistics & numerical data , Adult , Aged , Female , Glomerular Filtration Rate , Humans , Kidney Function Tests/methods , Kidney Function Tests/statistics & numerical data , Male , Middle Aged , Models, Biological , Models, Theoretical , Observer Variation , Prospective Studies , Radionuclide Imaging/methods , Radionuclide Imaging/statistics & numerical data , Reproducibility of Results , Young AdultABSTRACT
Objective: To analyze the long-term efficacy and safety of holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia. Materials and Methods: A total of 127 patients who underwent HoLEP at our institution between 2013 and 2015 were included. Patients were observed for 5 years postoperatively. We evaluated the length of the surgery, the mass of the removed tissue, prostate-specific antigen level, the maximal flow rate (Qmax), postvoid residual (PVR), the length of catheterization and hospitalization, and the International Prostate Symptom Score (IPSS) and IPSS quality of life (QoL) at each clinic visit. Results: PVR, Qmax, IPSS, and QoL all improved significantly immediately after the operation (p < 0.001). By the end of the 5th postoperative year, all the parameters showed a statistically meaningful decline: Qmax reduced by 5.8 mL/s (22.6%) and IPSS by 1.4 points (29.1%). Around 8.6% of the patients continued therapy with α-blockers. There were no differences in efficacy by the age of the patients or the volume of the prostate. Long-term complications and need for repeat operations were not affected by the volume of the prostate or patient age. Conclusions: The improvement of PVR, Qmax, IPSS, and QoL score seen in the early postoperative period after performing HoLEP remains evident at 5 years postoperatively. Long-term complications and the need for reoperation do not depend on the age of the patient or on the initial volume of the prostate.
